Jasper Therapeutics, Inc. (JSPR)
Automate Your Wheel Strategy on JSPR
With Tiblio's Option Bot, you can configure your own wheel strategy including JSPR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JSPR
- Rev/Share 0.0782
- Book/Share 1.5644
- PB 1.0994
- Debt/Equity 0.0917
- CurrentRatio 2.0959
- ROIC -3.3686
- MktCap 27954420.0
- FreeCF/Share -6.4132
- PFCF -0.2902
- PE -0.4025
- Debt/Assets 0.0464
- DivYield 0
- ROE -1.2165
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 2
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | JSPR | BMO Capital Markets | Outperform | Market Perform | -- | $4 | July 8, 2025 |
| Downgrade | JSPR | RBC Capital Mkts | Outperform | Sector Perform | -- | $5 | July 8, 2025 |
| Downgrade | JSPR | William Blair | Outperform | Market Perform | -- | -- | July 7, 2025 |
| Downgrade | JSPR | Cantor Fitzgerald | Overweight | Neutral | -- | -- | July 7, 2025 |
| Initiation | JSPR | UBS | -- | Buy | -- | $38 | Feb. 13, 2025 |
| Initiation | JSPR | BMO Capital Markets | -- | Outperform | -- | $63 | Dec. 6, 2024 |
| Initiation | JSPR | JMP Securities | -- | Mkt Outperform | -- | $70 | Sept. 9, 2024 |
News
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers.
Read More
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
Published: November 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
JSPR DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Published: November 17, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Jasper to Contact Him Directly to Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 17, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" …
Read More
Deadline Soon: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Published: November 17, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 18, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO PARTICIP.
Read More
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers.
Read More
JSPR DEADLINE: Faruqi & Faruqi Reminds Jasper Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 18 , 2025 - JSPR
Published: November 14, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Nov. 14, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the …
Read More
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 13, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 13, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR) have opportunity to lead the securities fraud class action lawsuit.
Read More
JSPR DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR
Published: November 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Read More
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 13, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.
Read More
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 12, 2025 by: PRNewsWire
Sentiment: Neutral
BENSALEM, Pa. , Nov. 12, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Read More
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 10, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”).
Read More
JSPR Deadline: Rosen Law Firm Urges Jasper Therapeutics, Inc. (NASDAQ: JSPR) Stockholders to Contact the Firm for Information About Their Rights
Published: November 07, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors there is a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR), between November 30, 2023 and July 3, 2025. Jasper is a clinical-stage biotechnology company. For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Jasper Therapeutics, Inc.
Read More
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
Published: November 07, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Published: November 07, 2025 by: Newsfile Corp
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - November 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" …
Read More
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.
Read More
Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Published: November 04, 2025 by: PRNewsWire
Sentiment: Neutral
LOS ANGELES , Nov. 4, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Jasper Therapeutics, Inc. ("Jasper" or the "Company") (NASDAQ: JSPR). IF YOU SUFFERED A LOSS ON YOUR JASPER INVESTMENTS, CLICK HERE BEFORE NOVEMBER 18, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Read More
JSPR DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – JSPR
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.
Read More
JSPR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Jasper To Contact Him Directly To Discuss Their Options
Read More
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
Published: November 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”).
Read More
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: November 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.
Read More
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: October 31, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.
Read More
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options
Read More
Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR
Published: October 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.
Read More
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: October 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 28, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”), are encouraged to contact the firm before November 18, 2025.
Read More
Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Published: October 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”).
Read More
JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Published: October 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) and certain of its officers.
Read More
JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit
Published: October 24, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Oct. 24, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline. So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Jasper
Published: October 23, 2025 by: PRNewsWire
Sentiment: Neutral
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Jasper Therapeutics, Inc. ("Jasper" or the …
Read More
About Jasper Therapeutics, Inc. (JSPR)
- IPO Date 2020-01-10
- Website https://jaspertherapeutics.com
- Industry Biotechnology
- CEO Ronald A. Martell
- Employees 64